AP
GILD icon

Antipodes Partners’s Gilead Sciences GILD Stock Holding History

Antipodes Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-557
Closed -$77.6K – 138
2026
Q1 		$77.6K Hold
557
– – ﹤0.01% 97
2025
Q4 		$68.4K Buy
+557
New +$67.7K ﹤0.01% 99
2025
Q2 		– Sell
-1,078
Closed -$121K – 112
2025
Q1 		$121K Buy
+1,078
New +$111K ﹤0.01% 70
2023
Q2 		– Sell
-1,204,538
Closed -$99.9M – 73
2023
Q1 		$99.9M Sell
1,204,538
-112,203
-9% -$9.29M 3.46% 14
2022
Q4 		$113M Buy
1,316,741
+249,941
+23% +$19.8M 4.06% 7
2022
Q3 		$65.8M Buy
+1,066,800
New +$67.3M 2.64% 15
2020
Q4 		– Sell
-355,411
Closed -$22.5M – 35
2020
Q3 		$22.5M Sell
355,411
-542,431
-60% -$37.6M 1.03% 30
2020
Q2 		$69.1M Buy
897,842
+7,475
+0.8% +$573K 3.13% 13
2020
Q1 		$66.6M Sell
890,367
-618,729
-41% -$42.8M 3.48% 16
2019
Q4 		$98.1M Sell
1,509,096
-315,194
-17% -$20.5M 4.42% 11
2019
Q3 		$116M Sell
1,824,290
-49,715
-3% -$3.25M 5.52% 6
2019
Q2 		$127M Buy
1,874,005
+479,034
+34% +$31.5M 5.81% 7
2019
Q1 		$90.7M Sell
1,394,971
-304,953
-18% -$20.3M 4.48% 11
2018
Q4 		$106M Sell
1,699,924
-218,787
-11% -$15.3M 5.25% 9
2018
Q3 		$148M Sell
1,918,711
-159,846
-8% -$12.1M 6.88% 8
2018
Q2 		$147M Sell
2,078,557
-627,295
-23% -$44.3M 7% 3
2018
Q1 		$204M Buy
2,705,852
+909,370
+51% +$72.3M 9.15% 1
2017
Q4 		$129M Buy
1,796,482
+518,890
+41% +$39.4M 7.54% 4
2017
Q3 		$103M Buy
1,277,592
+182,235
+17% +$13.9M 7.6% 2
2017
Q2 		$77.5M Buy
1,095,357
+313,939
+40% +$20.9M 10.21% 2
2017
Q1 		$55.6M Buy
781,418
+148,226
+23% +$10.4M 9.84% 2
2016
Q4 		$45.6M Buy
+633,192
New +$47.1M 10.25% 2

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Antipodes Partners's GILD Position: Q2 2026 in Review

Antipodes Partners sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 557 shares — an estimated $77.6K sold.

Antipodes Partners first reported a position in GILD in Q4 2016 and held it in 22 quarters. The position peaked at $204M in Q1 2018. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Antipodes Partners reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • Antipodes Partners sold 557 Gilead Sciences shares in Q2 2026, an estimated $77.6K.
  • Antipodes Partners first reported a position in Gilead Sciences in Q4 2016 and held it in 22 quarters.
  • Antipodes Partners's Gilead Sciences position peaked at $204M in Q1 2018.
  • 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.